Trials / Completed
CompletedNCT04868708
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
A Multicenter, Open-label, Phase II Study of AK104（an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Akeso · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end point is safety. The secondary end point is efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK104 | Subjects will receive AK104 intravenously. |
| BIOLOGICAL | Bevacizumab | Subjects will receive Bevacizumab intravenously. |
| DRUG | Paclitaxel | Subjects will receive Paclitaxel intravenously. |
| DRUG | Cisplatin or Carboplatin | Subjects will receive Cisplatin or Carboplatin intravenously. |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
- First posted
- 2021-05-03
- Last updated
- 2025-03-04
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04868708. Inclusion in this directory is not an endorsement.